Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Patent Interference
January 29, 2014 17:01 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 29, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix to Raise $106.7 Million Through Registered Direct Offering
January 28, 2014 08:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 28, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Reports Sustained Virologic Response Rate (SVR4) for Phase II All-Oral Combination Study of Samatasvir (IDX719), a Potent, Pan-Genotypic HCV NS5A Inhibitor, and Simeprevir
January 13, 2014 07:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 13, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
January 07, 2014 08:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 7, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the 32nd Annual J.P. Morgan...
Idenix Pharmaceuticals Appoints Jacques Dumas, Ph.D., as Chief Scientific Officer
January 06, 2014 08:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Jan. 6, 2014 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Declaration of Senior Party in a Second Patent Interference by the USPTO
December 09, 2013 08:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Dec. 9, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Announces Initiation of Enrollment in a Phase II All-Oral Combination Study of Samatasvir (IDX719), Simeprevir, and TMC647055 for the Treatment of Hepatitis C Virus (HCV) Infection
December 02, 2013 07:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals Files Patent Infringement and Interference Lawsuits Against Gilead Sciences
December 02, 2013 07:00 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human...
Idenix Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
November 25, 2013 16:05 ET
|
Idenix Pharmaceuticals
CAMBRIDGE, Mass., Nov. 25, 2013 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), announced today that Idenix management will participate in a fireside chat discussion at the 2013...
Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2013 Financial Results and Provides HCV Pipeline Update
October 30, 2013 16:05 ET
|
Idenix Pharmaceuticals
-- Enrollment initiated for a phase I/II clinical trial for IDX21437, a next-generation uridine nucleotide prodrug inhibitor for the treatment of hepatitis C virus infection (HCV)
-- Initiation...